A 70-year-old Japanese man underwent living-donor renal transplantation, with his wife being the donor, in June 2011 for end-stage renal dysfunction. He started receiving low-dose everolimus for immunosuppression from September 2012. Three months later he gradually developed dyspnea (mMRC [modified Medical Research Council] Breathlessness Scale grade 2). His chest computed tomography (CT) scan showed ground-glass opacity. At first, opportunistic infections were suspected and empirical therapies were started. However, the bronchoalveolar lavage fluid (BALF) demonstrated negative results for infection. The percentage of lymphocytes in BALF had significantly increased (54%), and a transbronchial lung biospy (TBLB) specimen showed organizing pneumonia. Drug-induced pneumonitis was suspected, and low-dose everolimus was stopped. After which the patient's symptoms and CT findings improved. We eventually diagnosed a case of low-dose everolimus-induced pneumonitis. Although everolimus-induced pneumonitis is frequently observed in cases of advanced renal cell carcinoma, low-dose everolimus-induced pneumonitis is rare and has never been reported in Japan. To the best of our knowledge, this is the first case of low-dose everolimus-induced pneumonitis in this country.